Literature DB >> 3139573

Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.

P S Sim1, R W Stephens, D R Fayle, W F Doe.   

Abstract

Total urokinase-type plasminogen activator (u-PA) content (proenzyme plus active enzyme) was significantly higher in 20 colorectal carcinomas and in 27 adenomatous polyps than in metaplastic polyps and autologous normal mucosa. u-PA content was also markedly increased in adenomatous polyps and autologous colonic mucosa removed from familial polyposis coli patients. Using a new monoclonal antibody technique to distinguish the proenzyme of u-PA from the active enzyme, we found that 70% of the u-PA in polyp and cancer tissue was present in the proenzyme form compared to 47% in normal colonic mucosa. For colon cancers, there was a significant correlation between their stage of invasiveness and the levels of proenzyme. No correlation was observed between the u-PA content of adenomatous polyps and their size or degree of dysplasia. Study of the u-PA content of the colonic mucosa may offer a useful biochemical correlate of epithelial cell transformation in the colon.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139573     DOI: 10.1002/ijc.2910420402

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas.

Authors:  I Sordat; P Chaubert; P Protiva; L Guillou; L Mazzucchelli; E Saraga; J Benhattar; C Trân-Thang; A L Blum; G Dorta; B Sordat
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

2.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.

Authors:  J Grøndahl-Hansen; E Ralfkiaer; L T Kirkeby; P Kristensen; L R Lund; K Danø
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

3.  Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover.

Authors:  P R Gibson; I Birchall; O Rosella; V Albert; C F Finch; D H Barkla; G P Young
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

4.  Cell associated urokinase activity and colonic epithelial cells in health and disease.

Authors:  P R Gibson; E van de Pol; W F Doe
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

5.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

6.  Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.

Authors:  P A de Bruin; H W Verspaget; G Griffioen; J H Verheijen; G Dooijewaard; C B Lamers
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

7.  Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.

Authors:  P Protiva; I Sordat; P Chaubert; E Saraga; C Trân-Thang; B Sordat; A L Blum; G Dorta
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx.

Authors:  S Parolini; D Flagiello; A Cinquetti; R Gozzi; S Cristini; J Cappiello; P Nicolai; M Rusnati; M Presta; M M Tosatti
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

9.  The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.

Authors:  Y H Kook; J Adamski; A Zelent; L Ossowski
Journal:  EMBO J       Date:  1994-09-01       Impact factor: 11.598

10.  Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.

Authors:  H Naitoh; Y Eguchi; H Ueyama; M Kodama; T Hattori
Journal:  Jpn J Cancer Res       Date:  1995-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.